Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...

The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

At 12 months, 88% of patients on Calquence showed no disease progression compared to 68% for the control arm. The safety and tolerability of Calquence was consistent with its established profile.

Calquence (acalabrutinib) is a prescription drug that’s used to treat certain types of leukemia and lymphoma, which are blood cancers. Calquence can cause side effects that range from mild to ...

Calquence starts working as soon as you start taking it. But it can take time to see results on laboratory or imaging tests. You’ll likely continue taking Calquence for as long as it’s ...

Positive” results from the AMPLIFY Phase III trial showed AstraZeneca’s (AZN) Calquence in combination with venetoclax demonstrated a ...

Calquence (acalabrutinib) is a brand-name oral tablet that’s prescribed for certain types of cancer in adults. As with other drugs, Calquence can cause side effects, such as low levels of blood ...